Oncology

Iovance’s tumor infiltrating lymphocyte (TIL) therapy is the first cellular therapy to earn this indication, with the phase 3, confirmatory TILVANCE-301 trial set to verify its clinical benefit.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The Associate Professor of Medicine at Harvard Medical School shared her outlook on the trajectory of CAR T-cell therapy for treating solid tumors.

Hemogenyx noted that the agency confirmed all issues pointed out in the initial clinical hold letter from June 2023 had been sufficiently addressed by the company.

The BAFFR-CAR T-cell therapy is being investigated in a phase 1 single-center and phase 1 multicenter trial in B-ALL and B-NHL.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The chief scientific officer at Omega Therapeutics discussed how the MYCHELANGEO-1 trial may validate the company’s OEC platform.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CDR-Life also recently presented positive preclinical data at the November 2023 SITC Annual Meeting.

The assistant professor at MD Anderson Cancer Center discussed a trial she is leading at MD Anderson with NK cells and cetuximab in colorectal cancer.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive™ team.

For World Cancer Day, held annually on February 4, take a look at the stories that have stood out in oncology cell therapy so far this year.

The Prescription Drug User Fee Act (PDUFA) target action date has been set for August 4, 2024.

Review top news and interview highlights from the week ending February 2, 2024.

Vor Bio recently also announced data from the phase 1/2 trial of trem-cel.

The Associate Professor of Medicine at Harvard Medical School discussed CAR T’s journey to treating solid tumors.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Kyverna has also announced data on its proprietary CAR-T manufacturing process, Ingenui-T.

The company also shared that it has manufactured sufficient IDP-023 to supply the Phase 1 clinical trial through the second half of 2024.

FT825 is an iPSC-derived multiplexed-engineered, CAR T-cell therapy targeting HER2 with a novel antigen binding domain.

Sana also recently announced data from the first patient treated with its CD19-targeted CAR.

Review top news and interview highlights from the week ending January 26, 2024.

The internal medicine resident physician at University of Kansas Medical Center also discussed highlights from the ASH 2023 meeting.

BriaCell also shared specific positive data from one patient with proptosis and ocular pain.

The European Medicines Agency Committee for Advanced Therapies will likewise hold a SAG-O meeting regarding the Type II variation application for the CAR-T in the EU.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The immune therapy is a replication-incompetent human tumor cell line designed to conjugate to and prime resting natural killer cells.

The associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed research he was excited to see at ASH 2023 and in the field in general.

The agency does not have plans for an advisory committee meeting to discuss obe-cel, which is an investigational autologous CD19-directed CAR-T therapy.